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1Department
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2Department

of Healthcare Policy & Research, Weill Cornell Medicine, New York, NY

Abstract
PURPOSE—The aim of the study was to compare prostate cancer–specific mortality (PCSM) in
young men with clinically localized prostate cancer treated by either external beam radiation
(EBRT) alone or brachytherapy with or without external beam radiation.
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METHODS AND MATERIALS—Utilizing the Surveillance, Epidemiology and End Results
database, 15,505 patients ≤60 years of age diagnosed with prostate cancer between 2004 and 2009
and treated with radiation therapy alone were identified. Incidence of PCSM was determined for
both groups and compared using competing risk models.
RESULTS—The overall 8-year PCSM for the study population was 1.9% (95% confidence
interval [CI]: 1.6–2.2). For patients treated with EBRT or brachytherapy with or without external
beam, the 8-year PCSM was found to be 2.8% (CI: 2.2–3.4) and 1.2% (CI: 0.9–1.6), respectively
(p < 0.001). Univariable analysis demonstrated that brachytherapy was associated with lower
PCSM risk (hazard ratio = 0.40; CI: 0.30–0.54; p < 0.001). High Gleason risk category, black race,
higher Tumor (T) stage, and higher grade were all associated with greater mortality risk (p < 0.01).
On multivariable analysis, brachytherapy continued to be associated with a significantly lower
mortality risk (hazard ratio = 0.65; CI: 0.47–0.89;p = 0.008). Subgroup analyses found that among
those with Gleason score ≥8, younger patients had increased risk of PCSM (p = 0.001).
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CONCLUSIONS—In men ≤60 years of age with prostate cancer, radiation therapy continues to
offer excellent outcomes. After adjusting for relevant variables, the use of brachytherapy was
associated with reduced PCSM compared to treatment with EBRT alone.
Keywords
Brachytherapy; Prostate cancer; SEER; Outcomes
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Introduction
The most effective definitive treatment for clinically localized prostate cancer in young men
(aged ≤60 years) has been the subject of much debate within the clinical and research
community. Traditionally, there has been a bias toward a recommendation of radical
prostatectomy in this patient population due to a perception that radiation therapy produced
poorer clinical outcomes and higher relapse rates attributable to their longer life expectancy
(1). Current research, however, is demonstrating that age may not be a significant prognostic
factor for either biochemical failure or prostate cancer–specific mortality (PCSM) in men
who receive radiotherapy alone for prostate cancer (2, 3).
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Research is now focusing on the specific role radiation can play as monotherapy for prostate
cancer treatment. Recent studies, including the ASCENDE-RT (Androgen Suppression
Combined with Elective Nodal and Dose Escalated Radiation Therapy) trial, have compared
outcomes between external beam radiotherapy alone or combined with a brachytherapy
boost and found that brachytherapy resulted in a significant improvement in relapse-free
survival and PCSM when compared to external beam radiation (EBRT) alone (4–6). The
influence of age on these outcomes, however, has not been fully investigated.
Given this current research context, the purpose of this study therefore was to compare the
PCSM in young men (≤60 years of age at the time of diagnosis) with clinically localized
prostate cancer treated by either EBRT alone or brachytherapy with or without external
beam radiation (BRT ± EBRT). In so doing, we hope to explore the role radiation therapy
can play in the treatment of this disease and the impact of age on outcomes in these patients.

Methods and materials
Author Manuscript

Patients meeting this study’s eligibility criteria were identified using the Surveillance,
Epidemiology and End Results (SEER) Database (7). This database contains incidence and
survival statistics from 18 population-based cancer registries (1973–2010), representing
approximately 28 percent of the U.S. population. Even though all SEER database
information remains deidentified, institutional review board approval was obtained before
performing the analyses (approval #569264).
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The study population included men 60 years old or younger who were diagnosed with
prostate adenocarcinoma between 2004 and 2009. International Classification of Diseases
for Oncology code 8140/3 was used when selecting histological type. Patients were selected
who were treated with radiation therapy, including EBRT only or BRT ± EBRT. Patients
who had received radical prostatectomy at any point during treatment were excluded, as
were patients with unknown radiation type. A total of 15,505 patients met these criteria and
were included in the overall analysis.
Demographic data retrieved from the SEER database included subject age, race, marital
status, age at the time of diagnosis, and geographic location. Age was analyzed as both a
continuous variable as well as a categorical variable (≤45 years and >45–60 years). Race
was categorized as black or other (white, American Indian/AK Native, Asian/Pacific
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Islander), based on SEER coding. Location was divided into north central, north east, south,
and west regions.
Treatment type was categorized as either EBRT or BRT ± EBRT. Pathologic data included
SEER classification of tumor grade (I or II, III or IV, NA), Gleason risk category (low risk ≤
7 or high risk ≥8), and tumor (T) (TNM) stage (T1 or ≥T2). No patients with positive nodes
or metastatic disease were included.
Survival time was calculated starting at the date of diagnosis to the date of death. If death
was not observed, patients were censored at the date of last followup. Cause of death was
determined using SEER site-specific death codes and categorized as being due to prostate
cancer or other causes.
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Statistical analysis

Author Manuscript

Demographic and pathologic data were extracted for the entire cohort. Continuous variables
were presented as a median (interquartile range) and tested with Kruskal–Wallis tests.
Categorical variables were presented as N (%) and tested using χ2 tests. Given that the
brachytherapy only and the brachytherapy with external beam radiation groups behaved
similarly on statistical analysis and that the number of patients in each cohort was small,
these groups were combined and compared to those who received EBRT only. All-cause
mortality (ACM) and PCSM were estimated for each treatment modality using Fine and
Gray’s subhazard regression methods for competing risks. Plots of cumulative incidence
were created to visually depict the association between treatment and mortality. Eight-year
cumulative incidence rates were estimated and compared using Wald-based tests.
Univariable and multivariable subhazard regression methods were also performed within
select subgroups. All statistical tests were two sided with statistical significance evaluated at
the 0.05 alpha level and confidence intervals (CIs) presented at the 95% level. All analyses
were performed using R v3.2.3 (R Development Core 2008).

Results
Our population included 15,505 men. Of those, 6555 (43.5%) had undergone EBRT only,
and 8500 (56.5%) had received brachytherapy (BRT ± EBRT). The median followup time
for the entire study population was 5.7 years (interquartile range: 4.25–7.1 years).
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Patient demographic information and clinical characteristics are listed in Table 1, and the
frequency of events by radiation type and followup stratified by survival status can be seen
in Table 1. Patients who received EBRT only tended to have higher grade disease (Grade III
or IV) (47.1% vs. 30.1%), higher Gleason risk category (≥8) (12.3% vs. 4.9%), and a larger
percentage were black (30.1% vs. 22.7%) (p < 0.001).
The overall 8-year cumulative incidence of PCSM for the study population was 1.9% (CI:
1.6–2.2), whereas the cumulative incidence of ACM was 8.3% (CI: 7.7–9.0). For patients
treated with EBRT or BRT ± EBRT, the cumulative 8-year PCSM incidence was found to be
2.8% (CI: 2.2–3.4) and 1.2% (CI: 0.9–1.6), respectively (p < 0.001) (Fig. 1).
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Univariable analysis examining PCSM (Table 2) demonstrated that brachytherapy was
associated with lower PCSM risk (hazard ratio [HR] = 0.40; CI: 0.30–0.54; p < 0.001).
Within the group aged 35–59 years, older age was numerically associated with a reduction in
PCSM, but this result was not statistically significant (HR = 0.98; CI: 0.94–1.01; p = 0.200).
High Gleason risk category, black race, higher TNM stage, and higher grade were all
associated with greater PCSM risk (p < 0.01). On multivariable analysis (controlling for
high Gleason risk category, age, race, marital status, TNM stage, and grade), brachytherapy
continued to be associated with a significantly lower mortality risk (HR = 0.65; CI: 0.47–
0.89; p = 0.008) (Table 3). Sensitivity analysis using propensity scores with these same
predictors revealed identical results. Univariable and multivariable analyses examining ACM
can be seen in eTable 2.

Author Manuscript

Subsequent univariable and multivariable analyses exploring PCSM stratified by Gleason
risk group continued to show a reduction in mortality in each of these subgroups (Tables 4
and 5). Age was not associated with risk of PCSM among those with Gleason score ≤7, but
among those with Gleason score ≥8, older patients had a significantly lower mortality risk
(HR = 0.91; CI: 0.86–0.96; p = 0.001). Interaction terms between age and treatment were
not significant, suggesting no differences in benefit across subgroups (eTable 3).

Discussion

Author Manuscript

Prostate cancer provides a unique situation in which several treatment modalities are
available, but there is a lack of randomized studies to assist patients in choosing the
treatment that is right for them. Because of this, young men often face difficult decisions
regarding the management of their illness, and the inherent treatment risks, side effects, and
quality of life implications become extremely important in their choice of treatment. These
are some of the reasons why the best treatment for localized prostate cancer in young men
continues to be strongly debated. This investigation sought to analyze PCSM in young men
with clinically localized prostate cancer treated with EBRT only or BRT ± EBRT. In so
doing, we hope to add to the debate regarding treatment options in this population of
patients.

Author Manuscript

Our results demonstrated a statistically significant decrease in 8-year PCSM with the use of
brachytherapy (BRT ± EBRT) when compared to EBRT alone (1.2% [CI: 0.9–1.6] and 2.8
[CI: 2.2–3.4]; p < 0.001). Furthermore, our univariable data showed that brachytherapy was
associated with lower PCSM risk (HR = 0.40; CI: 0.30–0.54; p ≤ 0.001) with an even more
pronounced effect seen on multivariable analysis (HR = 0.65; CI: 0.47–0.89; p = 0.008).
These results are consistent with those seen by Hoskin et al. (5) in their Phase III clinical
trial exploring outcomes with dose escalation using an high-dose-rate (HDR) brachytherapy
boost. They were able to demonstrate 5-, 7-, and 10-year relapse-free survival rates of 75%,
66%, and 46% for the boost group compared to 61%, 48%, and 39% for EBRT alone (p =
0.04, log-rank test), suggesting that an improvement in relapse-free survival can be realized
with brachytherapy.
Clinical evidence demonstrates that escalated radiation dose strongly impacts biochemical
outcomes in prostate cancer, with the best outcomes seen when doses of 75 Gy or higher are
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used (8–11). The challenge becomes achieving these high doses of radiation without
exceeding the limits of tissue tolerance for the surrounding structures, particularly the
bladder and rectum. Brachytherapy is a realistic means of achieving this balance. Martinez
et al. (12) treated 207 patients with 46 Gy pelvic EBRT and increasing HDR brachytherapy
boost doses (5.5–11.5 Gy/ fraction) and were able to demonstrate improved 5-year
biochemical control rates in the high-dose group (87% vs. 52%; p < 0.001). Grade 3
gastrointestinal and genitourinary complication rates were 0.5–9%. In a similar study,
Zwahlen et al. (13) examined outcomes with dose escalation using HDR brachytherapy and
three-dimensional conformal external beam radiotherapy (3DCRT), compared to treatment
with 3DCRT alone. They found 5- and 7-year biochemical control rates of 82.5% and
80.3%, respectively, for the 3DCRT + BRT group and 81.3% and 71%, respectively, for
3DCRT alone. Grade 3 late urinary and rectal morbidity rates were 7.1% and 0%,
respectively. As such, the combination of brachytherapy with eternal beam radiation not
only achieves the escalated doses required for favorable outcomes but does so with minimal
toxicity (14, 15).

Author Manuscript

Recent research, however, has suggested that high-risk prostate cancer represents a
heterogeneous disease with variable outcomes dependent on the number of risk factors.
Joniau et al. (16) developed a pretreatment prognostic model for prostate cancer–specific
survival in which high Gleason risk disease was stratified into three prognostic subgroups:
good, intermediate, and poor. They were able to demonstrate that overall survival, clinical
progression-free survival, and histopathologic outcomes significantly worsened as you
advanced from good to poor prognosis subgroups. Building on this work and the premise
that some patients with high Gleason risk disease may benefit from less aggressive therapy,
Muralidhar et al. (17) examined the PCSM in stratified high-risk prostate cancer patients
treated with either EBRT alone or EBRT with a brachyther-apy boost (EBRT + BT). They
were able to establish similar 5-year PCSM in patients with favorable high-risk disease
regardless of whether they were treated with EBRT + BT or EBRT alone (1.6% vs. 1.8%; p
= 0.258). Their results also showed that those with an unfavorable prognosis had a
significantly reduced rate of PCSM at 5 years if treated with EBRT + BT compared to EBRT
alone (3.9% vs. 5.3%; p = 0.022). This not only supports the theory of the heterogeneous
nature of high-risk prostate cancer but also supports the use of a brachytherapy boost in
patients with unfavorable prognosis. A well-designed prospective randomized trial would be
required to definitively determine the benefit or harm of a brachytherapy boost in these
subsets of high-risk disease.
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The question of age as an important predictor of PCSM is a significant one. This has become
even more crucial due to the routine implementation of prostate specific antigen screening
and increased public awareness of prostate cancer which has resulted in greater numbers of
younger patients being diagnosed with this disease (18). Age is a significant contributing
factor in decision-making and often dictates the treatments that are offered to patients. In
fact, one population-based study established not only that young men comprise an
increasingly large proportion of patients with newly diagnosed prostate cancer, but also that
physicians showed a strong bias toward treatment with radical prostatectomy in this subset
of patients (19). Furthermore, younger men treated with radiation therapy may be more
likely to receive higher doses of radiation than older men, and as previously mentioned,
Brachytherapy. Author manuscript; available in PMC 2018 March 01.
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escalated radiation dose has been shown to be associated with improved outcomes. These
age-related differences in approach stem from the perception that younger patients have
more aggressive disease and that radiation therapy may produce poorer clinical outcomes
and higher relapse rates attributable to longer life expectancy (1).
Our results showed no statistically significant association between age and PCSM on
univariable and multivariable analyses. However, those diagnosed at a younger age and with
a Gleason score ≥8 had poorer prostate cancer–specific survival than older patients with
Gleason score ≥8 (p = 0.001). Furthermore, interaction terms between age and treatment
were not significant and thus do not suggest that a particular age range showed a greater
difference between outcomes in the two groups studied. Patients would therefore benefit
equally from radiation therapy regardless of age.

Author Manuscript

This is in keeping with the results seen in the published literature. Shapiro et al. (20), in their
study of the long-term outcomes in younger men (<60 yrs) following permanent prostate
brachytherapy, found that age was not a significant predictor of outcome. They
demonstrated, via a subgroup analysis, that younger patients showed similar biochemical
recurrence rates to that of older patients and concluded that brachytherapy can be used as
definitive first-line treatment option for men of all ages. They suggested, however, that age
can be used as a unique surrogate of other strongly associated, coexisting factors. Other
recent studies have drawn similar conclusions (3, 21).

Author Manuscript

The lack of age-related differences in outcomes may be explained by the fact that when
dose-escalated ranges of radiation are used, outcomes are equivalent between younger and
older patients. This had previously been discussed by both Zelefsky et al. (22) and Klayton
et al. (2) who concluded that biochemical control is equivalent across age groups once
appropriate doses of radiation are used.
Our study specifically looked at patients who received EBRT vs. BRT ± EBRT We made no
distinction between patients receiving brachytherapy as monotherapy and those who
received dose escalation utilizing a brachytherapy boost. We also made no differentiation
between low-dose-rate and HDR brachytherapy. These are limitations of our study and
restrict the interpretation of our results.
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Our study has other inherent limitations. Although the SEER database remains the definitive
resource for cancer incidence and survival data in the United States, there are potential
shortcomings to its use that warrant discussion. Although it contains retrospective
information on over six million in situ and invasive cancer cases (7), its coverage is limited
to only 28% of the total U.S. population, and minority groups and urban communities tend
to be overrepre-sented. This compromises the generalizability of results. In addition, data
regarding particular clinicopathologic factors of prognostic significance, including
information regarding tumor recurrence, late metastasis, prostate specific antigen readings,
hormonal therapy, and specifics of radiation therapy (such as technology, dose, isotope used,
and dose rate), are not readily available. Information on toxicity and quality of life
parameters were also not obtainable. Furthermore, because data are gathered from centers all
across the country, quality assurance and the standardization of treatment among patients
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cannot be guaranteed (23). Finally, advances in radiotherapy protocols ensure that current
treatments are vastly superior to those offered a decade ago, and as a result, data may not
accurately reflect the outcomes and risks for men treated in the 21st century. In the 1990s,
the predominant treatment technique was conventional EBRT to a median dose of 65–70 Gy.
Since that time, the availability of 3D conformal radiation treatment planning and the
introduction of intensity-modulated radiation therapy have radically improved outcomes and
minimized long-term toxicity when compared to conventional EBRT (9). Notwithstanding
these deficiencies, this analysis remains pertinent as it directly reflects practice patterns in
the United States and allows for a baseline comparison of outcomes in prostate cancer.

Conclusions

Author Manuscript

In men ≤60 years of age with prostate cancer, radiation therapy continues to offer excellent
outcomes. After adjusting for relevant variables, the use of brachytherapy was associated
with reduced PCSM compared to treatment with EBRT alone. There were no differences in
this association across Gleason risk category or age, suggesting that these groups would
benefit equally from radiation therapy.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1.

Cumulative incidence curves for prostate cancer–specific mortality and all-cause mortality
by treatment modality. BRT = brachytherapy; EBRT = external beam radiation.
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Demographic and tumor characteristics of study population (n = 16,605)
Characteristic

EBRT (%)

BRT ± EBRT (%)

Overall

8081 (48.7)

8524 (51.3)

Outcome

p-Value

Overall (%)
16,605

<0.001

Alive

7382 (91.4)

8099 (95.0)

Dead–prostate

172 (2.1)

65 (0.8)

Dead–nonprostate

527 (6.5)

360 (4.2)

15,481 (93.2)
237 (1.4)
887 (5.3)

Months of followup

66 (50, 84)

70 (53, 87)

<0.001

68 (51, 85)

Months of followup among survivors

68 (51, 86)

70 (54, 87)

<0.001

69 (53, 86)

Age (median [IQR])

56 (53, 58)

56 (53, 58)

0.002

56 (53, 58)

Age (mean ± SD)

55.1 ± 3.6

55.0 ± 3.7

Age categorical

Author Manuscript

≤45 years
46–60 years

NA

55.1 ± 3.6

0.025
134 (1.7)

183 (2.1)

7947 (98.3)

8341 (97.9)

4344 (53.8)

2538 (30.1)

Grade
III/IV

0.002

317 (1.9)
16,288 (98.1)
<0.001

0 (0.0)

6912 (41.6)

1 (0.0)

Gleason–risk category

1 (0.0)
<0.001

Low risk = 6/7

6826 (84.5)

8104 (95.1)

High risk = 8+

1255 (15.5)

420 (4.9)

Married

4973 (61.5)

5964 (70.0)

10,937 (65.9)

Nonmarried

2563 (31.7)

2095 (24.6)

4658 (28.1)

545 (6.7)

465 (5.5)

1010 (6.1)

Black

2244 (27.8)

1932 (22.7)

4176 (25.1)

Other

5725 (70.8)

6510 (67.4)

12,235 (73.7)

112 (1.4)

82 (1.0)

959 (11.9)

572 (6.7)

1531 (9.2)

Northeast

1399 (17.3)

1286 (15.1)

2685 (16.2)

South

1822 (22.5)

2926 (34.3)

4748 (28.6)

West

3901 (48.3)

3740 (43.9)

Marital status

NA

Author Manuscript

<0.001

Region
North central

1675 (10.1)
<0.001

Race

NA

14,930 (89.9)

194 (1.2)
<0.001

Tumor (T) stagea

7641 (46.0)
<0.001

T1

5196 (64.3)

5969 (70.0)

11,165 (67.2)

T2+

2885 (35.7)

2555 (30.0)

5440 (32.8)

Author Manuscript

EBRT = external beam radiation therapy; BRT ± EBRT = brachytherapy with or without external beam; IQR = interquartile range.
Categorical variables present count (percent), whereas continuous measures present median (interquartile range) unless otherwise stated.

a

N+, M1 were excluded.
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Table 2

Author Manuscript

Univariable analysis examining prostate cancer–specific mortality using the Fine and Gray proportional
subhazards model for competing risks
Variable

HR (95% CI)

p-Value

0.34 (0.26.0–0.46)

<0.001

9.96 (7.72–12.85)

<0.001

0.98 (0.95–1.02)

0.330

1.33 (1.01–1.75)

0.045

1.21 (0.92–1.60)

0.170

2.04 (1.58–2.63)

<0.001

8.34 (5.88–11.84)

<0.001

Radiation type (vs. EBRT)
BRT ± EBRT
Gleason (vs. ≤7)
High risk ≥ 8
Age at diagnosis
Years
Race (vs. non-black)
Black
Marital status (vs. married)

Author Manuscript

Unmarried
TNM stage (vs. T1)
T2+
Grade (vs. I/II)
III/IV

HR = hazard ratio; CI = confidence interval; EBRT = external beam radiation therapy; BRT ± EBRT = brachytherapy with or without external
beam.

Author Manuscript
Author Manuscript
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Table 3

Author Manuscript

Multivariable analysis examining prostate cancer–specific mortality using the Fine and Gray proportional
subhazards model for competing risks
Variables

HR (95% CI)

p-Value

Radiation type (vs. EBRT)
BRT ± EBRT

0.65 (0.48–0.89)

0.006

4.68 (3.48–6.29)

<0.001

0.98 (0.94–1.01)

0.200

1.22 (0.90–1.64)

0.190

1.10 (0.82–1.47)

0.530

1.30 (0.99–1.70)

0.059

3.74 (2.46–5.70)

<0.001

Gleason (vs. ≤7)
High risk ≥ 8
Age at diagnosis
Years
Race (vs. non-black)
Black
Marital status (vs. married)

Author Manuscript

Unmarried
TNM stage (vs. T1)
T2+
Grade (vs. I/II)
III/IV

HR = hazard ratio; CI = confidence interval; EBRT = external beam radiation therapy; BRT ± EBRT = brachytherapy with or without external
beam.

Author Manuscript
Author Manuscript
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Table 4

Author Manuscript

Multivariable analysis examining prostate cancer–specific mortality using the Fine and Gray proportional
subhazards model for competing risks with interactions between Gleason risk category and treatment modality
Variables

HR (95% CI)

p-Value

Radiation type (vs. EBRT)
BRT ± EBRT

0.99 (0.62–1.56)

0.950

Gleason (vs. = 7)
Low risk ≤ 6

0.49 (0.20–1.19)

0.120

High risk ≥ 8

5.66 (3.97–8.07)

<0.001

0.98 (0.94–1.01)

0.180

1.18 (0.88–1.60)

0.270

1.11 (0.83–1.49)

0.470

1.50 (0.70–3.22)

0.300

BRT ± EBRT and low risk ≤6

0.45 (0.20–1.05)

0.064

BRT ± EBRT and high risk ≥8

0.54 (0.27–1.07)

0.075

Age at diagnosis
Years
Race (vs. non-black)
Black

Author Manuscript

Marital status (vs. married)
Unmarried
Grade (vs. I/II)
III/IV
Interactions

HR = hazard ratio; CI = confidence interval; EBRT = external beam radiation therapy; BRT ± EBRT = brachytherapy with or without external
beam.

Author Manuscript
Author Manuscript
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Table 5

Author Manuscript

Univariable and multivariable analyses examining prostate cancer–specific mortality stratified by Gleason risk
category using the Fine and Gray proportional subhazards model for competing risks
Variables

HR (95% CI)

p-Value

0.55 (0.38–0.80)

0.002

0.50 (0.30–0.83)

0.007

0.60 (0.40–0.89)

0.011

1.02 (0.97–1.08)

0.370

1.50 (0.97–2.33)

0.067

1.22 (0.80–1.86)

0.350

1.83 (1.26–2.67)

0.002

0.53 (0.32–0.88)

0.014

0.94 (0.90–0.99)

0.010

1.11 (0.74–1.68)

0.610

1.02 (0.68–1.53)

0.920

1.06 (0.73–1.53)

0.760

Univariable
Low risk ≤ 7
Radiation type (vs. EBRT)
BRT ± EBRT
High risk ≥ 8
Radiation type (vs. EBRT)
BRT ± EBRT
Multivariable
Low risk ≤ 7

Author Manuscript

Radiation type (vs. EBRT)
BRT ± EBRT
Age at diagnosis
Years
Race (vs. non-black)
Black
Marital status (vs. married)
Unmarried
TNM stage (vs. T1)
T2+
High risk ≥ 8
Radiation type (vs. EBRT)

Author Manuscript

BRT ± EBRT
Age at diagnosis
Years
Race (vs. non-black)
Black
Marital status (vs. married)
Unmarried
TNM stage (vs. T1)
T2+

HR = hazard ratio; CI = confidence interval; EBRT = external beam radiation therapy; BRT ± EBRT = brachytherapy with or without external
beam.

Author Manuscript
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